Close Menu

NEW YORK – BridgeBio Pharma subsidiary QED Therapeutics said on Wednesday that the US Food and Drug Administration accepted its new drug application for infigratinib to treat patients with FGFR-altered bile duct cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.